Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00978523 · ClinicalTrials.gov registry record · Phase 1
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
A Phase 1 study of Lymphoma and Solid Tumors, sponsored by Arno Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 3
- Study locations
NCT00978523 is a Phase 1 study of Lymphoma and Solid Tumors that has completed, run by Arno Therapeutics. The registered enrollment target is 35 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00978523, a Phase 1 study of Lymphoma and Solid Tumors, has completed, sponsored by Arno Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of AR-12 by describing dose-limiting toxicities (DLTs), and thereby establishing the maximum tolerated dose (MTD) or, in the absence of reaching an MTD, a recommended dose (RD) for additional study of oral AR-12 administered daily in cycles of 28 days (28 consecutive days of once daily treatment with at least a 7-day break between the first and second treatment cycles and recovery of toxicity to grade 1 or less, with no planned off-treatment days between subsequent cycles).
Conditions Studied
Interventions
- DRUG AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)
Study Locations (3)
Arizona
- TGen Clinical Research Services at Scottsdale Healthcare - Scottsdale
Ohio
- The Ohio State University - Comprehensive Cancer Center - Columbus
Surrey
- Royal Marsden Hospital - Sutton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00978523
The ClinicalTrials.gov registry entry for NCT00978523 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is Arno Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide) is the first listed.
NCT00978523 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Ohio, Surrey.
Frequently Asked Questions
What is clinical trial NCT00978523 about?
NCT00978523 is a clinical study titled "Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma". The primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of AR-12 by describing dose-limiting toxicities (DLTs), and thereby establishing the maximum tolerated dose (MTD) or, in the absence of reaching an MTD, a reco...
What is the current status of trial NCT00978523?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2009-08. Estimated completion is 2013-11.
What conditions does trial NCT00978523 study?
This clinical trial studies the following conditions: Lymphoma, Solid Tumors.
What interventions are being tested in trial NCT00978523?
The interventions under investigation include: AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide) (DRUG).
Who is sponsoring clinical trial NCT00978523?
This trial is sponsored by Arno Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00978523 being conducted?
This trial has 3 study locations across Arizona, Ohio, Surrey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.